Category Archives: News

Clarity Pharmaceuticals Announces the US FDA Grants Rare Paediatric Disease Designation to 64Cu-SARTATE™, a diagnostic for the clinical management of neuroblastoma

Sydney, Australia 9 September 2020 – Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Paediatric Disease Designation (RPDD) to 64Cu-SARTATE™, a diagnostic for the clinical management of neuroblastoma. Dr Alan Taylor, Clarity’s Executive Chairman, commented,…

First patient treated with Clarity’s copper-64 SAR-Bombesin in breast cancer clinical trial

Sydney, Australia 28 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been treated in the C-BOBCAT study (Copper-64 BOmbesin in Breast CAncer Trial). The C-BOBCAT trial is a first-in-human, investigator-led clinical trial investigating 64Cu-SAR-Bombesin (SAR-BBN) in patients with hormone…

Clarity Pharmaceuticals opens SARTATE™ neuroblastoma clinical trial

Sydney, Australia 23 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has opened its trial of 67Cu-SARTATE™ for paediatric patients with neuroblastoma at Memorial Sloan Kettering Cancer Center (MSK) in New York City and recruitment has commenced. “We are very excited to…

Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets

Sydney, Australia and Los Angeles, California 21 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, and ImaginAb, Inc., a company that harnesses the specificity of monoclonal antibodies, have entered into a collaboration agreement to develop new targeted theranostic (diagnostic and therapy) products for a broad range of cancer…

Dr Michael Ironside Appointed Director of Operations at Clarity Pharmaceuticals

Sydney, Australia 1 June 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Michael Ironside as Director of Operations. Dr Ironside has over 25 years of experience in senior roles in the highly regulated global pharmaceutical industry, including key positions in Europe,…

Prof. Oliver Sartor Joins Clarity’s Advisory Board

Sydney, Australia 19 March 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Prof. Oliver Sartor has joined Clarity’s Advisory Board. Prof. Sartor is a medical oncologist and an internationally recognised expert in prostate cancer. He is the Laborde Professor for Cancer Research, Medical Director…

Clarity appoints Dr Gillies O’Bryan-Tear to Chair Newly Formed Global Clinical Development Group

Sydney, Australia 31 March 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear will be chairing Clarity’s newly formed Global Clinical Development group. Dr O’Bryan-Tear joined the pharmaceutical industry in 1986 where he has spent 30 years in clinical development, medical management and…